Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial
In brief
Tumor treating fields delay pain worsening by 2.7 months in pancreatic cancer
In a secondary analysis of a randomized trial involving 571 patients, adding tumor treating fields to chemotherapy extended the time before pain worsened from 7.4 to 10.1 months; global health status also deteriorated later, and opioid use began later. These patient-reported benefits support the treatment's value, but the analysis was open-label and does not establish how patients experience the added therapy day to day.
- Journal
- JAMA network open (Q1)
- Published
- 2 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Teresa Macarulla, Vincent Picozzi, Sreenivasa R Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, et al.
- PMID
- 43024239
- DOI
- 10.1001/jamanetworkopen.2026.41241
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 15 November 2026): Phase III trial quality-of-life analysis of TTFields plus chemotherapy
Abstract
IMPORTANCE: The PANOVA-3 trial demonstrated the survival benefit and tolerability of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel, but understanding the impact of TTFields therapy on quality of life (QoL) and pain is important for clinical decision-making. OBJECTIVE: To analyze the impact of TTFields therapy concomitant with gemcitabine and nab-paclitaxel on QoL and pain outcomes using prospective data from PANOVA-3. DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified secondary analysis of PANOVA-3, which was a global, open-label, multicenter, phase 3 randomized clinical trial in adult patients with previously untreated locally advanced unresectable pancreatic adenocarcinoma (LA-PAC). A total of 571 patients were randomized between May 1, 2018, and March 31, 2023, with follow-up completed October 31, 2024. Data analysis was performed from November 2024 to May 2025. INTERVENTION: Patients were randomized 1:1 to receive either TTFields therapy (150 kHz) with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously on days 1, 8, and 15 of 28-day cycles. Duration of follow-up was 18 months. MAIN OUTCOMES AND MEASURES: QoL was measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire and the 26-item pancreatic cancer module. End points were mean changes from baseline QoL scores, deterioration-free survival of QoL, and time to opioid use. An analysis of pain medication use was performed post hoc. RESULTS: At baseline, 562 patients (median [IQR] age, 67 [31-90] years; 295 [52.5%] female), including 279 of 285 patients in the TTFields plus gemcitabine and nab-paclitaxel arm and 283 of 286 patients in the gemcitabine and nab-paclitaxel arm, completed the EORTC QLQ-C30 questionnaire. Global health status was stable during the 26-month follow-up in both study arms. Digestive symptoms, pain, and pancreatic pain were improved from 2 months after treatment initiation throughout treatment and follow-up in the TTFields plus gemcitabine and nab-paclitaxel arm. TTFields plus gemcitabine and nab-paclitaxel was associated with longer deterioration-free survival for global health status than gemcitabine and nab-paclitaxel alone (median [IQR], 7.1 [3.5-14.8] vs 5.7 [2.3-11.5] months; hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .02). Longer deterioration-free survival was also observed for most items on the digestive symptoms scales (indigestion and altered bowel habit were similar between the 2 arms). Median (IQR) deterioration-free survival was significantly longer with TTFields plus gemcitabine and nab-paclitaxel for pain (10.1 [4.0-20.9] vs 7.4 [3.5-14.5] months; HR, 0.70; 95% CI, 0.54-0.89; P = .003) and pancreatic pain (14.7 [6.2-46.2] vs 10.2 [5.6-18.2] months; HR, 0.69; 95% CI, 0.52-0.90; P = .006) as was median time to opioid use in the modified intention-to-treat population (9.3 [3.9-18.6] vs 6.7 [1.1-16.3] months; HR, 0.72; 95% CI, 0.55-0.93; P = .01). CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial found that TTFields therapy with gemcitabine and nab-paclitaxel improved QoL and provided clinically meaningful benefits in pain outcomes compared with gemcitabine and nab-paclitaxel alone. This study's results suggest that TTFields therapy with gemicitabine and nab-paclitaxel is practice-changing for patients with unresectable LA-PAC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03377491.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.